Home › Funds › MPM BioImpact LLC › ACRS
MPM BioImpact LLC position in ACRS
ACLARIS THERAPEUTICS INC · Health Care
MPM BioImpact LLC reported holding 1,042,467 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$5.5M, representing 0.34% of its reported portfolio and ranking #35 among its reported holdings. MPM BioImpact LLC has disclosed ACRS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's ACRS position evolved
MPM BioImpact LLC first disclosed a stake in ACRS in Q1 2026 at 391,918 shares (US$1.5M). The position peaked in Q2 2026 at 1,042,467 shares, worth US$5.5M. Across 2 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,042,467 shares valued at US$5.5M — an increase of 650,549 shares quarter over quarter.. Notable position changes include a 166% increase in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 391.92K | $1.47M | New |
| Q2 2026 | 1.04M | $5.51M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACRS and 13F data
ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), BML Capital Management, LLC (US$63.3M), Deep Track Capital, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACRS
- RA CAPITAL MANAGEMENT, L.P. 12.72M sh · $67.30M · Q2 2026
- BML Capital Management, LLC 11.97M sh · $63.35M · Q2 2026
- Deep Track Capital, LP 9.35M sh · $49.44M · Q2 2026
- Vivo Capital, LLC 6.69M sh · $35.41M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.93M sh · $26.06M · Q2 2026
- Rock Springs Capital Management LP 4.33M sh · $22.91M · Q2 2026
- Decheng Capital LLC 4.04M sh · $21.38M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.95M sh · $10.30M · Q2 2026
- Kalehua Capital Management LLC 1.83M sh · $9.69M · Q2 2026
- Jones Hill Capital LP 1.76M sh · $9.31M · Q2 2026
- Palo Alto Investors LP 1.61M sh · $8.54M · Q2 2026
- Aldebaran Capital, LLC 936.73K sh · $4.96M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held ACRS?
MPM BioImpact LLC has disclosed ACRS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is MPM BioImpact LLC's current position in ACRS?
As of Q2 2026, MPM BioImpact LLC holds 1.04M shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $5.51M, representing 0.34% of its reported portfolio and ranking #35.
Has MPM BioImpact LLC been buying or selling ACRS?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC increased its position in ACRS. The position peaked in Q2 2026 at 1.04M shares.
Which other funds hold ACRS?
Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Deep Track Capital, LP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.